[go: up one dir, main page]

WO2005103693A3 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production - Google Patents

Methods, compositions and compound assays for inhibiting amyloid-beta protein production Download PDF

Info

Publication number
WO2005103693A3
WO2005103693A3 PCT/EP2005/051883 EP2005051883W WO2005103693A3 WO 2005103693 A3 WO2005103693 A3 WO 2005103693A3 EP 2005051883 W EP2005051883 W EP 2005051883W WO 2005103693 A3 WO2005103693 A3 WO 2005103693A3
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
beta
compositions
methods
protein production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/051883
Other languages
French (fr)
Other versions
WO2005103693A2 (en
Inventor
Koenraad Frederik Fl Spittaels
Marcel Hoffmann
Pascal Gerard Merchiers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos Genomics NV
Original Assignee
Galapagos Genomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/005625 external-priority patent/WO2005103707A1/en
Application filed by Galapagos Genomics NV filed Critical Galapagos Genomics NV
Publication of WO2005103693A2 publication Critical patent/WO2005103693A2/en
Publication of WO2005103693A3 publication Critical patent/WO2005103693A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a vasopressin receptor polypeptide, or fragment thereof, and measuring a compound-polypeptide property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of vasopressin receptor expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.
PCT/EP2005/051883 2004-04-27 2005-04-26 Methods, compositions and compound assays for inhibiting amyloid-beta protein production Ceased WO2005103693A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EPPCT/EP2004/004508 2004-04-27
EPPCT/EP2004/004508 2004-04-27
PCT/EP2004/005625 WO2005103707A1 (en) 2004-04-27 2004-05-21 Novel compounds for the treatment of alzheimer’s disease and methods for identifying same
EPPCT/EP2004/005625 2004-05-21
EPPCT/EP2004/011425 2004-10-08
EP2004011425 2004-10-08

Publications (2)

Publication Number Publication Date
WO2005103693A2 WO2005103693A2 (en) 2005-11-03
WO2005103693A3 true WO2005103693A3 (en) 2006-01-12

Family

ID=35045056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/051883 Ceased WO2005103693A2 (en) 2004-04-27 2005-04-26 Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Country Status (1)

Country Link
WO (1) WO2005103693A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293734A (en) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 Tolvaptan solid dispersion and preparation method thereof
WO2015009988A1 (en) * 2013-07-19 2015-01-22 The Johns Hopkins University Cardiac imaging methods and use in diagnosis and treatment of heart failure and related disease
TW202516009A (en) * 2023-10-10 2025-04-16 大陸商上海舶望製藥有限公司 Compositions and methods for inhibiting expression of amyloid precursor protein (app)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0880193A (en) * 1994-09-12 1996-03-26 Otsuka Pharmaceut Co Ltd Gene of angiovasopressin receptor
US5512563A (en) * 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512563A (en) * 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JPH0880193A (en) * 1994-09-12 1996-03-26 Otsuka Pharmaceut Co Ltd Gene of angiovasopressin receptor
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUYADER DOMINIQUE ET AL: "Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites", HEPATOLOGY, vol. 36, no. 5, November 2002 (2002-11-01), pages 1197 - 1205, XP002349170, ISSN: 0270-9139 *
KATO V ET AL: "DISTRIBUTION AND DEVELOPMENTAL CHANGES IN VASOPRESSIN V2 RECEPTOR MRNA IN RAT BRAIN", DIFFERENTIATION, SPRINGER VERLAG, DE, vol. 59, no. 3, March 1995 (1995-03-01), pages 163 - 169, XP001126248, ISSN: 0301-4681 *
NITSCH R M ET AL: "VASOPRESSIN AND BRADYKININ REGULATE SECRETORY PROCESSING OF THE AMYLOID PROTEIN PRECURSOR OF ALZHEIMER'S DISEASE", NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 23, no. 5, 1998, pages 807 - 814, XP009037707, ISSN: 0364-3190 *
PALM CATRIN ET AL: "The role of V2 vasopressin antagonists in hyponatremia", CARDIOVASCULAR RESEARCH, vol. 51, no. 3, 15 August 2001 (2001-08-15), pages 403 - 408, XP002349169, ISSN: 0008-6363 *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 07 31 July 1996 (1996-07-31) *

Also Published As

Publication number Publication date
WO2005103693A2 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
WO2005109000A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
Fitzgerald et al. Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson’s disease
US10557171B2 (en) Methods for the treatment of kidney fibrosis
EP3060582B1 (en) Assays for determining plasma kallikrein system biomarkers
CN102421919B (en) Using the method for the Axl biomarkers converted as Epithelial and stromal
WO2009067546A3 (en) Lung cancer markers and uses thereof
WO2008087035A3 (en) Screening method for anti-diabetic compounds
Hall et al. Immune checkpoint protein VSIG4 as a biomarker of aging in murine adipose tissue
Van Helmond et al. Oligomeric Aβ in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy
SI1745295T1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
Xin et al. Proteomics study reveals that the dysregulation of focal adhesion and ribosome contribute to early pregnancy loss
Leary Swan et al. Proteomics analysis of perilymph and cerebrospinal fluid in mouse
ZA200807766B (en) Inhibition of GASC1
WO2013023132A1 (en) Diagnostic and prognostic markers for cancer
EA201491411A1 (en) SOLUBLE MANF IN DESTRUCTION OF BETA CELLS OF THE REFERRAL GLAND
WO2005119262A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
EP2067034B1 (en) Eif4e regulon-based diagnostics
WO2005103693A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005103715A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2006053251A3 (en) Method of measuring amyloid-beta peptides
WO2005103692A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
BR112018002742B1 (en) EVACUATED BLOOD COLLECTION TUBE, METHOD FOR EVALUATION OF THE ENDOGENOUS LEVEL OF CONTACT SYSTEM ACTIVATION IN A SUBJECT, METHOD FOR EVALUATION OF THE LEVEL OF A DRUG TARGETING THE CONTACT SYSTEM IN A SUBJECT AND METHOD FOR EVALUATING THE IMMUNOGENICITY OF A SUBJECT DRUG AIMING THE CONTACT SYSTEM
WO2007095378A3 (en) Mass tagging for quantitative analysis of biomolecules using 13c labeled phenylisocyanate
US20140323545A1 (en) Nitrated sphingosine 1-phosphate 3 receptor as a predictor of acute lung injury-associated mortality
US20250123292A1 (en) LG3 Assay

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase